Kiora Pharmaceuticals

11/12/2025

At Kiora Pharmaceuticals, we are dedicated to advancing therapies that have the potential to slow, stop, or restore lost vision. Our work is guided by science, but ultimately driven by the patients and families impacted by inherited retinal diseases.

These conditions can affect daily life in profound ways, and too often, treatment options are limited or unavailable. That’s why our team is committed to developing innovative, mutation-agnostic therapies designed to expand possibilities for patients—regardless of their genetic cause.

Every step forward in research brings us closer to a future where more people living with vision loss have access to meaningful treatment options.

Learn more about our mission at https://kiorapharma.com/

11/06/2025

KIO-104 is a potent, locally delivered small molecule in development to treat retinal inflammation.

By targeting the root cause of inflammation, KIO-104 aims to protect and improve vision in conditions such as posterior non-infectious uveitis, diabetic macular edema and other retinal inflammatory diseases.

🔗 Learn more about our pipeline at https://kiorapharma.com/pipeline-science/kio-104/

10/28/2025

Hear this inspiring story from one of Kiora Pharmaceuticals’ clinical trial participants, where she was delighted to be able to enjoy watching a bit of cricket on television. This everyday moment reflects the hope KIO-301 brings to those living with inherited retinal diseases.

Discover how KIO-301 is potentially revolutionizing vision restoration at https://bit.ly/Kiora_Home

10/22/2025

Our small-molecule photoswitch — KIO-301 is intended to restore functional vision in patients with late-stage inherited retinal diseases such as retinitis pigmentosa.

As Brian M. Strem, PhD, President & Chief Executive Officer of Kiora Pharmaceuticals explains, KIO-301 is a light‑responsive small molecule that, “literally change[s] shape in the presence or absence of light…capable of going into these retinal ganglion cells… and [turning] them into light‑sensing cells by altering some of their molecular…ion channels.”

This approach bypasses damaged rods and cones, targeting ‘alive’ retinal ganglion cells to enable a novel therapeutic modality for vision reactivation. Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

10/16/2025

When season 9 of Love Is Blind premiered on Netflix, viewers met Madison Maidenberg — a blinding eye disease advocate living with retinitis pigmentosa, a rare inherited retinal disease that may lead to vision loss.

Madison serves as a brand ambassador for the Foundation Fighting Blindness, helping to raise awareness and funds for research aimed at treating and curing retinal diseases. Her story is bringing national attention to the lived experiences of people with retinitis pigmentosa and the importance of continued innovation in vision restoration.

At Kiora Pharmaceuticals, we share that mission. We’re developing KIO-301, an investigational therapy designed to help restore lost vision for people affected by inherited retinal diseases like retinitis pigmentosa.

Read more about her story at https://parade.com/tv/love-is-blind-madison-maidenberg-retinitis-pigmentosa.

What you need to know about retinitis pigmentosa, which 'Love Is Blind' contestant Madison was diagnosed with.

10/13/2025

Innovation meets impact. We are proud to join the American Academy of Ophthalmology community at Eyecelerator @ AAO 2025, where industry’s leading minds advance the future of ophthalmic care. Our mission remains clear: to unlock new possibilities in vision therapies and transform patient outcomes through cutting-edge science and collaboration.

Register today at https://registration.experientevent.com/ShowOPH252.

10/08/2025

A participant in Kiora’s clinical trial recently shared a moment that changed everything: for the first time in years, he noticed the details on his television screen coming into focus. This personal milestone underscores the potential of KIO-301 — a targeted therapeutic designed to restore meaningful vision for people living with inherited retinal diseases.

Discover how KIO-301 is potentially revolutionizing vision restoration at https://bit.ly/Kiora_Home

09/30/2025

This is patient-reported evidence of vision restoration from an individual clinically diagnosed as having no light perception.

Within 48 hours of KIO-301 administration, this participant was also observed to have measurable changes as assessed by functional MRI. These early results support the potential of our small-molecule photoreceptor platform in addressing inherited retinal degenerative diseases.

We're advancing toward a future where sight may be restored — when hope often feels out of reach. Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

06/04/2025

As researchers continue to discover new gene variants linked to inherited blindness, the case for mutation-agnostic therapies grows stronger.

A recent study from the University of Oklahoma uncovered 20 newly identified gene variants in retinal disease – adding to an already complex genetic landscape.

While gene therapies remain a potentially powerful approach, they are often specific to a particular mutation. That’s why we’re developing KIO-301: a mutation-agnostic small molecule designed to restore light perception regardless of the underlying genetics.

It’s not about replacing gene therapies – but expanding options for patients. Mutation-agnostic approaches like 301 can work alone or alongside gene therapy, creating a more inclusive future for patients.

🔗 Read the study: https://eyewire.news/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases?c4src=article:infinite-scroll
🔬 Learn about KIO-301: https://bit.ly/Kiora_Home

05/27/2025

Our passion is to develop innovations in biology to transform patients’ everyday lives. It’s stories like this that remind us how those with inherited retinal diseases are affected even in the little moments, like playing with their dog. This Kiora Pharmaceuticals clinical trial participant noticed an inspiring improvement in her vision—she was able to see her dog more clearly than ever before!

KIO-301 offers a new possibility for those who may not have treatment options.

Learn more about KIO-301 and its potential impact on patients’ lives: https://bit.ly/KioraHome.

05/16/2025

📢 Advancing KIO-104 for Retinal Macular Edema

Kiora has received clearance to begin KLARITY, a Phase 2 clinical trial evaluating KIO-104, a DHODH inhibitor, for treating macular edema —a condition where inflammation plays a key role.
This follows a recent grant of a composition-of-matter patent, which strengthens the company’s IP protection. The patent specifically covers a distinct crystalline form of the drug that allows for optimized production, stability, and delivery—enhancing the potential of KIO-104.

Together, these milestones move KIO-104 closer to becoming a non-steroidal option for retinal inflammation.

🔗 Trial announcement:
https://ir.kiorapharma.com/news-events/news-releases/detail/227/kiora-receives-approval-to-initiate-klarity-a-phase-2-clinical-trial-of-kio-104-for-the-treatment-of-retinal-macular-edema

🔗 Patent news:
https://ir.kiorapharma.com/news-events/news-releases/detail/228/kiora-pharmaceuticals-secures-u-s-composition-of-matter-patent-expanding-protection-of-its-anti-inflammatory-compound-kio-104

05/05/2025

We’re excited that Romana Seda-Zehetner MSc MScTox, Director Preclinical Development at Kiora Pharmaceuticals, presented data from a preclinical study at ARVO 2025 demonstrating the potential of KIO-104 to treat proliferative vitreoretinopathy (PVR).

PVR, which has no approved therapies, is the leading complication following retinal detachment surgery. The condition results in scarring, which may lead to repeated retinal detachments as well as progressive and permanent vision loss. The poster presentation highlighted a novel anti-proliferative approach, demonstrating KIO-104 significantly reduced scar size and formation in an established model of PVR. By targeting T cell–mediated pathways, KIO-104 may offer a new therapeutic approach to reducing fibrotic scarring and preventing recurrent retinal detachment.

Glad to participate in ARVO and share how KIO-104 is shaping the future of ophthalmic treatments. Stay tuned for updates from the Kiora team.

Learn more here:
https://ir.kiorapharma.com/news-events/news-releases/detail/232/kiora-pharmaceuticals-presents-in-vivo-preclinical-data-at-arvo-2025-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy